Fig. 4

MYC drives tumor progression through CD47 and PD-L1. (A). Immunohistochemistry analysis of MYC through PCa tissue microarray; N: Normal prostate tissue, T: Prostate cancer tissue, LM: lymphatic metastases; (B). Immunofluorescence of MYC, PDL1, and CD47 in LNCap; (C). Bioinformatics analysis of binding sites of MYC to PDL1 and CD47; (D). MYCmRNA, PDL1mRNA, and CD47mRNA expression in LNCaP after MYC down-regulation. (E–F). MYC, PDL1, and CD47 western blot protein expression analysis in LNCaP; (G–H). Metastatic ability of LNCAP cells analyzed using transwell assay after down-regulation of MYC.